[A23-139] Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V
Last updated 06.06.2024
Project no.:
A23-139
Commission:
Commission awarded on 15.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Prophylaxis of cytomegalovirus reactivation and disease in adult cytomegalovirus-seropositive recipients of an allogeneic haematopoietic stem cell transplant
Hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-139_en
| Project no. | Title | Status |
|---|---|---|
| A23-137 | Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G18-03 | Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A24-48 | Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139 | Commission completed |
Federal Joint Committee (G-BA)
2024-06-06 A G-BA decision was published.